Climb Bio
CLYM
23 hedge funds and large institutions have $45.5M invested in Climb Bio in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 3 closing their positions.
3% more capital invested
Capital invested by funds: $44M → $45.5M (+$1.51M)
0% more funds holding
Funds holding: 23 → 23 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.62% less ownership
Funds ownership: 61.75% → 61.14% (-0.62%)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$629K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$97.6K |
| 3 |
Cerity Partners
New York
|
+$36K |
| 4 |
Renaissance Technologies
New York
|
+$27.6K |
| 5 |
Morgan Stanley
New York
|
+$4.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$319K |
| 2 |
Millennium Management
New York
|
-$104K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$38.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.61K |
| 5 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$1.68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$52 | -20 | -36% |
|
CLYM Hedge Fund Activity: Q4 2023 in Review
23 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q4 2023, worth a combined $45.5M — up 3.4% from $44M a quarter earlier.
Fund positioning in CLYM was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 8 trimmed.
The largest buyer was BML Capital Management, adding an estimated $629K. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $319K sold.
- 23 institutional investors held Climb Bio (CLYM) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $45.5M of Climb Bio stock for Q4 2023, up 3.4% quarter-over-quarter.
- 3 funds opened new Climb Bio positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest Climb Bio buyer in Q4 2023 was BML Capital Management, an estimated $629K added.
- The largest Climb Bio seller in Q4 2023 was Silverarc Capital Management, an estimated $319K sold.
Based on aggregated 13F filings for Q4 2023.